SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-395722"
 

Sökning: id:"swepub:oai:DiVA.org:uu-395722" > Postmenopausal cran...

Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B

Cabreus, Philip (författare)
Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden
Swartling, Carl (författare)
Uppsala universitet,Dermatologi och venereologi,Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden
Rystedt, Alma (författare)
Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden
 (creator_code:org_t)
2019-08-02
2019
Engelska.
Ingår i: Journal of dermatology (Print). - : WILEY. - 0385-2407 .- 1346-8138. ; 46:10, s. 874-878
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Hyperhidrosis can seriously impair patients' quality of life. Medical history, including heredity and hyperhidrosis during youth, as well as current age and time elapsed since menopause, is important to consider when distinguishing between postmenopausal hyperhidrosis and vasomotor symptoms to enable adequate treatment. This report concerns a subgroup of eight postmenopausal patients participating in a randomized controlled trial regarding botulinum toxin (Btx) type B treatment in craniofacial hyperhidrosis. Even though the sample size is small and the enrolment is not yet completed, the promising data collected hitherto are interesting to present in advance because this subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat. Patients were randomized to receive Btx type B or placebo. Measurements were performed before treatment and 3 +/- 1 weeks after. The Dermatology Life Quality Index (DLQI) score was improved for all patients after Btx type B treatment (n = 3) with a median decrease of 9 points (90% median improvement). The placebo group (n = 5) had a median increase of 2 points (-18% median decline). When the same group (n = 5) received Btx type B (open) the DLQI score decreased with a median of 7 points compared with baseline (91% median improvement). Treatment-related adverse events were temporary and did not prevent improvement of life quality. Furthermore, background data evaluation uncovered interesting findings regarding vasomotor symptoms in relation to postmenopausal hyperhidrosis. In conclusion, the results indicated that Btx type B seems to be a safe and effective treatment in postmenopausal craniofacial hyperhidrosis. Further research is encouraged.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)

Nyckelord

botulinum toxin
hyperhidrosis
NeuroBloc
postmenopause
sweating

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Cabreus, Philip
Swartling, Carl
Rystedt, Alma
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
och Dermatologi och ...
Artiklar i publikationen
Journal of derma ...
Av lärosätet
Uppsala universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy